BMO Capital Starts ARMO BioSciences, Inc. (ARMO) at Outperform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/15/2026
- S&P 500 ends higher as traders shift from AI to healthcare
- U.S. producer prices rise by 1.3% month-on-month in September
- Brent steady as US weighs easing sanctions on global 'shadow fleet'
- UBS now expects a third Fed rate hike after hot September inflation print
- Tesla-SpaceX Merger could be announced before December, Barclays says
- Nebius shares sink on CoreWeave's bond yield spike and insider sales
- IonQ prices $2 billion equity offering at $40 per share
- Rocket Lab delays Neutron rocket debut to 2027
- Bloom Energy stock falls as inflation data pressures markets
- Nasdaq ends sharply lower as hot inflation data stirs rate-hike worries
Jefferies Starts ARMO BioSciences, Inc. (ARMO) at Buy
February 20, 2018 2:23 AM ESTJefferies initiates coverage on ARMO BioSciences, Inc. (NASDAQ: ARMO) with a Buy rating and a price target of $61.00.
For an analyst ratings summary and ratings history on ARMO BioSciences, Inc. click here. For more ratings news on ARMO BioSciences, Inc. click here.
Shares of ARMO BioSciences, Inc. closed at $53.65 Friday.
... MoreBaird Starts ARMO BioSciences, Inc. (ARMO) at Outperform
February 20, 2018 1:57 AM ESTBaird initiates coverage on ARMO BioSciences, Inc. (NASDAQ: ARMO) with a Outperform rating and a price target of $67.00.
Analyst Brian Skorney comments "We see ARMO's pegylated, recombinant IL-10, AM0010, as a unique asset in the IO space. It has shown singleagent response... More



